CLINICAL TRIALS PROFILE FOR NAMENDA

All Clinical Trials for NAMENDA

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00120874 ↗	Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training	Completed	Fisher Center for Alzheimer's Research Foundation	Phase 4	2006-08-01	The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease.
NCT00120874 ↗	Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training	Completed	Forest Laboratories	Phase 4	2006-08-01	The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease.
NCT00120874 ↗	Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training	Completed	New York University School of Medicine	Phase 4	2006-08-01	The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease.
NCT00120874 ↗	Memantine and Comprehensive, Individualized Management of Alzheimer's Disease and Caregiver Training	Completed	NYU Langone Health	Phase 4	2006-08-01	The purpose of this study is to determine whether a comprehensive, individualized management approach with caregiver training and medication with memantine will alleviate symptoms in community dwelling patients with moderate to severe Alzheimer's disease.
NCT00181298 ↗	Memantine in Systemic Lupus Erythematosus	Completed	Forest Laboratories	N/A	2006-03-01	Neuropsychiatric manifestations of Systemic Lupus Erythematosus (NPSLE) are both common and an important source of morbidity. Of the case definitions for NPSLE syndromes that have recently been developed, cognitive dysfunction appears to be the most prevalent. A novel mechanism is that a subset of SLE patients with cognitive dysfunction have antibodies in the NR2 glutamate receptor. We propose, in a double -blind placebo-controlled trial, to determine whether SLE patients, with or without the NR2 glutamate receptor antibody, have significant improvement using memantine, an inhibitor of the NMDA receptor.

Clinical Trial Conditions for NAMENDA

Condition Name

Condition Name for NAMENDA
Intervention	Trials
Alzheimer's Disease	6
Autism	4
Autism Spectrum Disorder	4
Traumatic Brain Injury	3

Condition MeSH

Condition MeSH for NAMENDA
Intervention	Trials
Disease	13
Cognitive Dysfunction	10
Autistic Disorder	8
Alzheimer Disease	8

Clinical Trial Locations for NAMENDA

Trials by Country

Trials by Country for NAMENDA
Location	Trials
United States	244
Canada	5
Spain	4
Korea, Republic of	4
Colombia	3

Trials by US State

Trials by US State for NAMENDA
Location	Trials
California	18
Massachusetts	17
New York	16
Maryland	10
Illinois	10

Clinical Trial Progress for NAMENDA

Clinical Trial Phase

Clinical Trial Phase for NAMENDA
Clinical Trial Phase	Trials
Phase 4	22
Phase 3	10
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for NAMENDA
Clinical Trial Phase	Trials
Completed	50
Recruiting	6
Terminated	5

Clinical Trial Sponsors for NAMENDA

Sponsor Name

Sponsor Name for NAMENDA
Sponsor	Trials
Forest Laboratories	28
Massachusetts General Hospital	10
National Cancer Institute (NCI)	5

Sponsor Type

Sponsor Type for NAMENDA
Sponsor	Trials
Other	98
Industry	31
NIH	13